The comment you reference is sufficiently vague that i am going to reserve judgement until i see data. TRIL has shown a tradeoff preclinically between efficacy and toxicity and went with the more active Fc in the clinic. stanford went with a weaker Fc to minimize toxicity. In this interview it seems clear the tox profile is even better than expected for the stanford drug, but if the TRIL data translates clinically it will be at the expense of efficacy, at least as monotherapy
News 
Market Data 
Discover 
